Trial 4K-17-1


A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

Type: Treatment
Phase: Phase III
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Other
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Varsha Tulpule, M.D.
Other Trial Staff:  Cheryl Kefauver, Coordinator, Lagrimas Ilagan, D.M., Roberto Tejada, Coordinator, Shamim Jhimlee, Coordinator, Honorina Enright, D.M., Amanda Luna, D.M., Charis Barg, Coordinator, Bartolo Santos, Coordinator, Gina LaBeaud, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.